Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Current Assets (2016 - 2025)

Celldex Therapeutics has reported Current Assets over the past 16 years, most recently at $534.7 million for Q4 2025.

  • Quarterly results put Current Assets at $534.7 million for Q4 2025, down 28.44% from a year ago — trailing twelve months through Dec 2025 was $534.7 million (down 28.44% YoY), and the annual figure for FY2025 was $534.7 million, down 28.44%.
  • Current Assets for Q4 2025 was $534.7 million at Celldex Therapeutics, down from $604.3 million in the prior quarter.
  • Over the last five years, Current Assets for CLDX hit a ceiling of $835.3 million in Q1 2024 and a floor of $167.6 million in Q2 2021.
  • Median Current Assets over the past 5 years was $418.7 million (2021), compared with a mean of $474.2 million.
  • Biggest five-year swings in Current Assets: surged 224.58% in 2021 and later decreased 28.44% in 2025.
  • Celldex Therapeutics' Current Assets stood at $410.8 million in 2021, then dropped by 22.67% to $317.7 million in 2022, then surged by 35.88% to $431.7 million in 2023, then skyrocketed by 73.08% to $747.2 million in 2024, then decreased by 28.44% to $534.7 million in 2025.
  • The last three reported values for Current Assets were $534.7 million (Q4 2025), $604.3 million (Q3 2025), and $648.4 million (Q2 2025) per Business Quant data.